pounds from all other psychotropic drugs. We underlined Ihe fact tllUt the psychomotor aspecls or the symplomatology, generally reversible wilh drugs, were of the same nature as those observed in epidemic encephalitis by eminent neurologists like P. Marie, Marikasco, J. Lhermitte et al. and his colleagucs.
The beginnings
Chlorpromazine (CPZ) was the leading neurolepticIhe name given to this class of drug in 1955. It was discovered in France and its psychiatric applications were investigaled in 1952 in Europe and in 1954 in America. Reserpine, a completely different chemical entity, was introduced into psychiatry almost simultaneously in 1954 in France, Swilzerland and America. The indications for bolh drugs in the psychoses were similar. Their effects on sleep and the autonomic nervous system had already been observed, but Steck was the first to describe the extrapyramidal side effecls.
The first international conferences were held in Paris and Milan in October 1955, and there the indicalions for and the resullS of Ireatment wilh both drugs were reviewed, confirming that they were indicated for chronic psychoses. At Ihe first meeting on psychotropic drugs, held in Milan in May 1957 (just preceding the birth of the ClNP), Delay and DenikeI' presented a phannacoclinical delinilion of neuroleptics based on the common similarities that difl'erenliated the early , .
The histOly of Ihe neuroleptics has been marked by a number of distinct phases since ils inception in 1952 and the recent inlroduction of several new compounds. 
Sedative action
Disinhibiling -action At Ole same session, Brill, reporting on the New York State experience, said that in 1955 a large-scale Olerapeutic programme with chlorpromazine and reserpine had been undertaken on 25 000 of the 93 000 patients. He had noted a reduction of 3000 in ti,e population instead of an expected increase of8000.The number of patients treated rose to 30 000 and in tile same period the measures of restraint and confinement 'fell from 25 per Olousand to 5.
With the growing practice of chemotherapy, two important questions arose regarding tile choice ofdrugs and their dosage. In France, tile introduction of a new phenothiazine, prochlorperazine, which seemed to have some disinhibitory (Olat is to say, "stimulant") effect also raised tile problem of therapeutic classification.
[n Europe, different types of classification have been proposed since 1960; the last clinical one, in 1971, adopted a bipolar scheme and divided tile compounds into four groups (Fig. 3) .
However, in Ole United States, Ole concept of CPZequivalent made its appearance; supported in particular by Ban and Davis, tilis was generally adopted on Ole other side of the Atlantic.
As early as 1956, the question of why dosages were The impact of drugs on the different parts of th.e dopamine system has led to a search for drugs acting especially on the limbic and meso-cortical structures.
Stimulates mood
I) d ,•
Stimulates vigilance
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The neurol9ptics: a historidIl survey , I include all neuroleptics (except levomepromazine which is not registered as an antipsychotic but as an antihypertensive drug) on a warning list in 1985.
To try to explain these unexpected complications we have drawn attention to several factors that may possibly be involved, First the posology; in the survey of Jeste and Wyatt (1981) concerning 12 000 patients studied over 20 years, the inclusion criteria required at least three months of treatment WiOl a total dose of up to 100 g of CPZ equivalent per day -even olOugh we have seen that an increase above 500 mg produces no better results.
A second point is the specificity of Ole drugs olemselves. We have classified the neuroleptics by taking into account their side effects; thus, autonomic side effects related to sedative compounds, and extrapyramidal sidẽ ffects io some "polyvalent" or disinhibitory compounds, This contlicts with the concept of CPZequivalent. In a study of "severe" tardive dyskinesia, Gardos and his colleagues (1984) showed that more than 50% of cases had been caused by only two compounds; fluoperazine and thiothixene, which in our experience are considered to be particularly prone to induce parkin-
sonism.
To try to clarify the problem of the nature of the drugs, Deniker and Poirier employed a data bank of psychotropic dmgs to propose an automatic classifica- From the beginning, neuroleptics had to face the consequences of adverse reactions. The first question put to us in the USA concerned the problem of jaundice with chlorpromazine. Later it was shown that the drug can induce microcanalicular obstruction of the biliary passages, Allergic reactions in nurses were avoided by adequate preparation of the tablets. A further impediment appeared with Ole so-called purple people. Some skin discolouration and ocular deposits occurred in patients who were photosensitive. This was the first adverse effect of high dosages to appear. Last but not least, were the tardive dyskinesias which were responsible for many problems in the United States and led the Food and Dlug Administration (FDA) to respond any better than those treated WiUl lower doses. This inflation of dosage plays a part, as we shall see, in f· the phenomenon of tardive dyskinesia.
tion using statistical computerized methods~Multifac-torial analysis of correspor.dences allowed us to make a definite separation of the cloud of neuroleptics from other psychotropic drugs. It is possible to distinguish two poles: below, the sedative compounds; and, above, the disinhibitors (Fig. 4) -as in the clinical, empirical classification shown in Fig.3 . Since at least 1983, it has been possible to explain the different properties of the neuroleptics by their different actions on the 01 and 02 postsynaptic dopaminergic receptors. Gardos had remarked· that thioridazine seemed to have a "protecting" effect against severe' tardive dyskinesia. Friedhof and his colleagues described an animal model of chronic tardive dyskinesia which showed that the best antagonist to ti,e abnormal movements was sulpiride which acted on the 02 receptors. Unfortunately, this benzamide is not available on the American market, owing to its endocrine side effects such as amenorrhoea and galactorrhoea (the lalter also affecting males). These endocrinological effects thus occur with a drug that is disinhibitory and a low inducer of extrapyramidal symptoms.
A final factor possibly implicated in the development oftardive dyskinesia concerns individual predisposition: mental retardation, organic damage, tlhe elderly, etc. It is known, for example, tilat tardive dyskinesia can appear in aged women independently of chemotherapy.
Neuroleplics and schizophrenia
The antipsychotic actions of the neuroleptics were once considered as "anti-schizophrenic". After the discovery of the anti-dopaminergic action of these drugs, the hypotllesis of a "hyper-dopaminergic" aetiology was proposed for this group of psychoses.
However, clinicians are well aware thatchem'otherapy is not illl aetiological treatment for the psychoses since different forms can be identified and we prefer to speak of schizophrenias in the plural.
Initially, ti,e neuroleptics are especially active against "productive" symptomatology such as excitation, hallucinations, and delusions. The early compounds are almost ineffective against the mood deficiency, social withdrawal and apathetic syndrome. With the introduction of drugs possessing disinhibilory properties, gradually some improvement was obtained in this regard. Yet ti,e dopaminergic tileory of schizophrenia retains little credibility for psychiatrists. However, Crow has proposed a double hypothesis: distinguishing between the "productive" and "defective" symptomatology of ti,e cI inical forms of psychosis, he correlates them with possible hyper-or hypo-dopaminergic dysregulation. This has still to be confmned.
Paradoxically, ti,ese researches seem to have overlooked the early anti-manic specific activity included in the general.defmition of neuroleptics proposed in 1957. When the antidepressants were discovered, it appeared 86 that they had theopposileeffects to neuroleptics on mood regulation. Neuroleptics are effective against mania and, rarely, can induce some degree of depression (for instance, with reserpine). In contrast, antidepressants resolve depressive states and sometimes can produce euphoric reversion of mood. TIley have anti-reserpine activities, thal is to say all anLi-neuroleptic action.
Today, mood regulation is well known as a function involved not only in manic-depressive disorders but also in different kinds of psychoses such as dysthymic ones. This approach can be used sometimes to treat the hypothymic or atllymic fonns which are the most resistant of the schizophrenias.
Requirements for the future
In the case of mania, modem psychiatry cannot accept that excited patients make trouble in our quiet wards. So, it is important to have very rapidly acting tranquillizers -acting in an hour, like droperidol, but droperidol has hypotensive side effects and, in acute cases, the injection has to be repeated every 2 or 3 hours. Thus we need a fast neuroleptic with a prolonged duration of action.
In the chronic psychoses, the more or less "resistant" patients are of two types. The first haye ilTeducible hallucinations or delusions, sometimes persisting unobtrusively. Neuroleptics have differing activities against hallucinations: the specific agents are the butyrophenones (especially haloperidol, triperidol and haloanisone), against flupenthixol illld loxapine. Thus, there still remains a need in this special indication.
The second type of resistant psychoses are those in which there is a deficit of mood or social retardation. In many chronic schizophrenias both are presel1l: persistent residual hallucinatory activity and loss of motivation and energy. Various means are available for combating this defective syndrome, for instance the use of Illore disinhibitory neuroleptics; the addition of antidepressants to the neuroleptic; or ti,e use of compounds such as carpipramine, in which the molecule has a tricyclic nucleus and butyrophenone-like structure. From both the pharmacological and the clinical points of view, tilis is neither a regular neuroleptic nor an antidepressant, even if it is an effective stimulant drug, especially in the chronic residual schizophrenias. But within this chemical group are other compounds (such as c1ocapramine, the chlorinate compound) that are true regular neuroleptics.
Among the dibenzo-oxazepines, amoxapine has botlh antidepressant and neuroleptic properties. Even if it is given only for depression, extrapyramidal side effects may sometimes appear.
In Another benzamide, remoxipride, is also a Dz blocker with clear-cuI antipsychotic action in the schizophrenias.
Conclusion
After 37 years,the neuroleptic story continues with new developments still to be examined. The face of madness , The neuroll~)tic~:. n historicnl suney l has been completely changed: nol only by means of psychopharmacology but also by the development of psychotherapy, sociotherapy and the rehabilitation of the patients in the community. But this metamorphosis of the insane or lunatic into a" ordinary patient has erased the clinically spectacular symptomatology of the past and we now have to keep our eyes and ears attuned if we are to observe the typical cases of psychopathology. The modern lists of criteria and the different types of rating scales are necessary for communication between specialized centres and wilh oUler disciplines, yet we must not forget that we are psychiatrists attentive to human behaviour and relations, and not just account,mts of quantitative methodology.
